Medtronic PLC (MDT), Actavis plc (ACT): Zweig-DiMenna Partners Top Picks from Healthcare Sector

Zweig-Dimenna Partners also holds 210,900 shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) valued at $41.89 million.  Valeant Pharmaceuticals is a Canadian pharmaceutical company that is focused on infectious diseases, dermatology and neurology. The second-largest shareholder of the company is Bill Ackman’s Pershing Square, which owns 19.47 million shares, valued at $3.87 billion. At the beginning of May, Ackman said at the Sohn Conference that Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s stock should be valued at $330 per share and compared the company to an early-stage Berkshire Hathaway. Another large shareholder of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is Jeff Ubben’s ValueAct Capital, which owns 19.38 million shares.

Next on the list is Bristol-Myers Squibb Co (NYSE:BMY), in which Zweig-Dimenna Partners held 583,942 shares worth $37.66 million at the end of March. Bristol-Myers Squibb Co is a biopharmaceutical company that develops and discovers innovative medicines for patients with serious diseases, whose stock gained more than 15% since the beginning of the year. Bristol-Myers Squibb Co (NYSE:BMY) posted a first quarter revenue of $4.04 billion, versus $3.81 billion a year earlier, while its earnings per share increased by 34% on the year to $0.71. The revenue growth was impacted by stronger sales of some of Bristol-Myers Squibb Co (NYSE:BMY)’s main drugs, such as immunotherapeutic drugs. Among the funds we track, the largest shareholders of Bristol-Myers are Samuel Isaly’s Orbimed Advisors and Phill Gross and Robert Atchinson’s Adage Capital Partners, which own 8.88 million shares and 7.05 million shares respectively.

Disclosure: none